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Background: Fetuin-A is a hepatokine linked to the development of insulin resistance. 
The purpose of this study was to determine if 60 days head-down-tilt (HDT) bed rest 
increased circulating fetuin-A and if it was linked to whole body insulin sensitivity (IS). 
Additionally, we examined whether reactive jump training (RJT) could alleviate the metabolic 
changes associated with bed rest.
Methods: 23 young men (29 ± 6 years, 181 ± 6 cm, 77 ± 7 kg) were randomized to a 
control (CTRL, n = 11) or RJT group (JUMP, n = 12) and exposed to 60 days of bed rest. 
Before and after bed rest, body composition and V 
. 
O2peak were measured and an oral 
glucose tolerance test was performed to estimate IS. Circulating lipids and fetuin-A were 
measured in fasting serum.
Results: Body weight, lean mass, and V 
. 
O2peak decreased in both groups following bed 
rest, with greater reductions in CTRL (p < 0.05). There was a main effect of time, but not 
the RJT intervention, for the increase in fetuin-A, triglycerides (TG), area under the curve 
for glucose (AUCG) and insulin (AUCI), and the decrease in Matsuda and tissue-specific 
IS (p < 0.05). Fetuin-A increased in participants who became less insulin sensitive 
(p = 0.019). In this subgroup, liver IS and adipose IS decreased (p < 0.05), while muscle 
IS was unchanged. In a subgroup, where IS did not decrease, fetuin-A did not change. 
Liver IS increased (p = 0.012), while muscle and adipose tissue IS remained unchanged.
Conclusions: In this study, we report an increase in circulating fetuin-A following 60 days 
of bed rest, concomitant with reduced IS, which could not be mitigated by RJT. The 
amount of fetuin-A released from the liver may be an important determinant of changes 
in whole body IS. In this regard, it may also be a useful biomarker of individual variation 
due to inactivity or lifestyle interventions.
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INTRODUCTION
Physical inactivity and exposure to microgravity induce aging-
like phenotypic changes that are associated with the etiology 
of many chronic diseases (Bergouignan et  al., 2011; Hart and 
Zernicke, 2020). The physiological changes in space and during 
head-down-tilt (HDT) bed rest, the Earth-based analogue of 
microgravity, have been well-described and include altered 
cardiovascular capacity, bone loss, muscle atrophy, impaired 
functional capacity, and metabolic dysregulation, among others 
(Bergouignan et al., 2011; Narici and de Boer, 2011; Ade et al., 
2015; Vico and Hargens, 2018; Konda et  al., 2019). There is 
evidence that underlying mechanisms, such as insulin resistance, 
play an important role in the regulation of whole body metabolic 
changes (Gratas-Delamarche et  al., 2014). Insulin resistance is 
a multi-faceted disruption of the action of insulin in skeletal 
muscle, adipose tissue, vasculature, brain, and the liver, leading 
to hyperinsulinemia and reduced glucose disposal (Cox-York 
and Pereira, 2020). It is also associated with impaired oxidative 
capacity, increased circulating and deposition of lipids, and 
metabolic inflexibility. These whole body and cellular changes 
have been observed following bed rest studies, even when 
energy balance is maintained (Bergouignan et  al., 2006, 2009, 
2011; Kenny et  al., 2017; Rudwill et  al., 2018). The severity 
of insulin resistance has been found to vary considerably 
between individuals and between the key target organs 
(Unnikrishnan, 2004; Abdul-Ghani et  al., 2007). Therefore, 
understanding the individual variability in insulin resistance 
could provide personalized information on disease etiology 
and individualized interventions to maintain health.
A key strategy for monitoring metabolic homeostasis is 
communication between peripheral tissues via secreted proteins, 
which perform autocrine, paracrine, and endocrine actions. 
Disruption of protein production and target-tissue action 
underpin the development of metabolic dysfunction including 
insulin resistance (Priest and Tontonoz, 2019). The quantitative 
measurement of circulating protein biomarkers is a relatively 
easy and minimally-invasive means of identifying and 
understanding the etiology of insulin resistance.
The liver is a major regulator of systemic glucose metabolism. 
Liver-derived proteins, known as hepatokines, are released into 
circulation and some of them are known to enhance or attenuate 
insulin sensitivity (Stefan and Häring, 2013; Iroz et  al., 2015; 
Choi, 2016). Fetuin-A is a novel hepatokine, encoded by the 
alpha-2-HS-glycoprotein (AHSG) gene in humans and is a 
known regulator of metabolism (Stefan and Häring, 2013). In 
particular, an increase in fetuin-A is associated with the 
development of insulin resistance and the pathophysiology of 
type 2 diabetes mellitus (T2DM). Fetuin-A impairs the insulin 
signaling cascade by binding to the tandem fibronectin type 
3 domains present on the extracellular portion of the 
transmembrane β-subunit of the insulin receptor, attenuating 
tyrosine kinase signaling and leading to reduced glucose uptake 
(Goustin et al., 2013; Ochieng et al., 2018). Additionally, fetuin-A 
has been proposed to inhibit the production of the insulin-
sensitizing hormone adiponectin in adipocytes, indirectly leading 
to a decrease in insulin sensitivity (Hennige et  al., 2008). 
Finally, fetuin-A is implicated in lipid-induced insulin resistance 
by acting as an intermediary between palmitate and toll-like 
receptor 4 (TLR4) leading to adipose tissue inflammation and 
insulin resistance (Pal et  al., 2012).
Exercise training, using a wide-range of modalities, is known 
to promote glucose control and improve insulin sensitivity in 
healthy and clinical populations (Ennequin et  al., 2019). One 
of the mechanisms that contributes to improved metabolic 
health is training-induced alterations in the production and 
secretion of pro-inflammatory and anti-inflammatory cytokines 
from tissues of metabolic importance. Numerous studies have 
reported that exercise training decreases the secretion of 
fetuin-A from the liver concomitant with improvements in 
whole body and liver insulin sensitivity in patients with 
metabolic disease (Malin et  al., 2013, 2014; Lee et  al., 2017; 
Ennequin et  al., 2019).
The purpose of this study was to determine if 60  days of 
extreme physical inactivity increased circulating fetuin-A and 
if those changes correlated with whole body insulin sensitivity. 
We  used the European Space Agency 60  day bed rest model, 
where subjects were maintained in energy balance, despite a 
decrease in physical activity. This unique approach means fat 
accumulation is not a confounding factor on the metabolic 
outcomes. In addition, we  examined whether reactive jump 
training (RJT), a countermeasure used to maintain skeletal 
muscle mass, was able to attenuate the deterioration in metabolic 
health that occurs with prolonged inactivity.
MATERIALS AND METHODS
General Study Information
This research was conducted as part of the “Reactive jumps 
in a sledge jump system as a countermeasure during long-
term bed rest” (RSL) study funded by the European Space 
Agency, which ran as two separate bed rest campaigns, 
commencing in August 2015 and January 2016, respectively. 
This parallel-design randomized controlled training study 
was conducted at the “envihab” facility at the German 
Aerospace Center (DLR). A detailed description of the subject 
recruitment procedures, experimental conditions, diet, 
countermeasure, and training protocol have been published 
previously (Kramer et  al., 2017b).
In brief, the study was split into three phases: a 15-day 
baseline data collection phase (BDC-15 to BDC-1), 60  days 
of strict 6° head-down-tilt bed rest (HDT1 to HDT60), followed 
by a post-intervention testing phase (R  +  0 to R  +  14), with 
a total duration of 90  days. Subjects were randomly assigned 
to a control group (CTRL) or intervention group involving 
Abbreviations: Adipose IR, Adipose tissue insulin resistance; AUCG, Area under 
the curve for glucose; AUCI, Area under the curve for insulin; BDC, Baseline 
data collection; BMI, Body mass index; CTRL, Control group; ELISA, Enzyme-
linked immunosorbent assay; HDT, Head-down-tilt; IS, Insulin sensitivity; JUMP, 
Jump countermeasure group; Liver IS, Liver insulin sensitivity; Muscle IS, Muscle 
insulin sensitivity; OGTT, Oral glucose tolerance test; RJT, Reactive jump training; 
PV, Plasma volume; T2DM, Type 2 diabetes mellitus; V . O2peak, Peak aerobic 
capacity.
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reactive jump exercise (JUMP). For the duration of the bed 
rest period, subjects remained at the 6° HDT angle for 24 h/day.
The inclusion criteria have been described previously 
(Kramer et  al., 2017b) but included men, aged 20–45  years, 
body mass index (BMI) 20–26 kg/m2, non-smoker, no medication, 
no history of bone fractures, non-competitive athlete, and no 
medical conditions. Initially, 24 male volunteers were enrolled 
for the study, however one subject discontinued during baseline 
data collection due to medical reasons unrelated to the study. 
In addition, two subjects were ambulated after 49-days HDT 
(CTRL) and 50-days HDT (JUMP) due to medical reasons 
but all post-bed rest data were collected except for V .  O2peak.
On HDT1, participants were randomly assigned to either 
the control group (CTRL, n  =  11, age 28  ±  6  years, BMI 
23.3  ±  2  kg/m2) or the countermeasure group (JUMP, n  =  12, 
age 30  ±  7  years, BMI 23.8  ±  2  kg/m2), which performed 
RJT 5–6  days per week in a horizontal sledge jump system. 
A total of 48 training sessions were completed during the 
HDT bed rest period. Each training session involved a varying 
amount of repetitive hops and countermovement jumps with 
an average load equal to or exceeding 80% of the individual’s 
body weight. The maximal workload in one session excluding 
breaks did not exceed 4  min. During the entire study, the 
subjects received a strictly controlled and individualized diet, 
which was tailored to maintain energy balance. The study 
protocols were approved by the Ethics Committee of the North 
Rhine Medical Association (Ärztekammer Nordrhein) in 
Düsseldorf, Germany, as well as the Federal Office for Radiation 
Protection (Bundesamt für Strahlenschutz). All subjects gave 
their written informed consent before commencing the study 
in accordance with the Declaration of Helsinki. This study 
was registered with the German Clinical Trial Registry 
(#DRKS00012946, 18th September 2017).
Body Weight and Body Composition
Measurements of body weight and body composition were 
taken on numerous days before and after bed rest. This is 
a large scale bed rest study and data are reported by different 
research groups. The core data have been published elsewhere 
(Kramer et  al., 2017b), however, this study has compared 
measurements of body weight and body composition recorded 
on BDC-3 and HDT60. Body weight was measured daily 
following the first urine void of the day (DVM 5703, 
Sartorius, Göttingen, Germany). Body composition was 
examined with dual-energy X-ray absorptiometry (DEXA), 
using the whole body scan feature on the Prodigy Full Pro 
(GE Healthcare GmbH, Solingen, Germany) and the 
manufacturer’s enCORE software (version 16.10.151) was 
used to generate automated reports of total lean mass, fat 
mass, and bone mineral content.
Peak Oxygen Consumption Test
Peak aerobic capacity (V. O2peak) was measured on BDC-8 and 
R + 1 using cycle ergometry (Lode, Groningen, The Netherlands) 
as previously described (Kramer et  al., 2017a). In brief, after 
an initial 5  min of seated rest, subjects were instructed to 
start pedaling and to maintain a cadence of 75 revolutions 
per minute (rpm). The warm-up consisted of 3  min cycling 
at 50  W, followed by 1  min stages, in which the load was 
increased by 25 W per stage until volitional exhaustion, despite 
strong verbal encouragement. If the peak respiratory exchange 
ratio (RER) did not exceed 1.10, the trial was deemed not 
exhaustive and not considered for further analyses. Due to 
the absence of post-bed rest data, two subjects were removed 
from our analysis of V
.
 O2peak.
Oral Glucose Tolerance Test
An oral glucose tolerance test (OGTT) was performed after 
a 12-h overnight fast, in the morning of BDC-5 and HDT59. 
A catheter was placed in the antecubital vein and blood samples 
were drawn before and at 30  min intervals (30, 60, 90, and 
120  min) after the ingestion of a 75  g glucose equivalent 
(ACCU Chek® Dextro OGT, Roche Diagnostics Deutschland 
GmbH, Mannheim) dissolved in 300 ml water. Following sample 
extraction, serum was left to coagulate at room temperature 
for 30  min before centrifugation, while vacutainers containing 
fluoride and EDTA were centrifuged immediately (184  ×  g, 
4°C, 10  min). Serum and plasma were then aliquoted and 
stored at −80°C until analysis.
Plasma Volume Correction
As the 6° HDT angle induces a fluid shift and consequent 
loss of plasma volume (PV), the change in PV was calculated 
and the concentrations of biochemical parameters following 
HDT bed rest were corrected for changes in hemoconcentration 
(Dill and Costill, 1974; Alis et  al., 2016). The change in PV 
(Δ%PV) was calculated as follows: Δ%PV  =  100*((Hbpre/
Hbpost)*(100–Htcpost)/(100–Htcpre)–1), where hemoglobin (Hb) 
is given in g/dL and hematocrit (Hct) is expressed as a percentage 
(%). To correct measured parameters for changes in PV, the 
following calculation was used: [parameter]c  =  [parameter]
u*(1  +  ΔPV(%)/100), where the c and u indices represent 
corrected and uncorrected concentrations, respectively.
Biochemical Analysis and Assays
Concentrations of glucose, non-esterified fatty acids (NEFA), 
total cholesterol, LDL-cholesterol (LDL), HDL-cholesterol (HDL), 
and triglycerides (TG) were measured using colorimetric assay 
kits on the Randox RX Daytona™ (Crumlin, United Kingdom). 
Serum insulin was quantified using an immunoassay method 
on the Cobas® 8000 modular analyser (module e602, Roche 
Diagnostics, North America). Area under the curve for glucose 
(AUCG) and insulin (AUCI) were calculated according to the 
trapezoidal rule. Indexes of insulin resistance and insulin 
sensitivity including the Matsuda index, liver insulin sensitivity 
(liver IS), muscle insulin sensitivity (muscle IS), and adipose 
tissue insulin resistance (adipose IR) were calculated using 
previously reported equations (Supplementary Material; Matsuda 
and DeFronzo, 1999; Abdul-Ghani et al., 2007; Lomonaco et al., 
2012). Using fasting serum samples from the OGTT, 
concentrations of fetuin-A were assayed in duplicate using the 
human fetuin-A quantikine ELISA kit, according to the 
Ward et al. Fetuin-A and Metabolic Variability
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manufacturer’s instructions (Cat No: DFTA00. R&D Systems 
Inc. Minneapolis, United  States). The intra-assay coefficient of 
variance (%CV) was 11%.
Statistical Analysis
All experimental data are presented as mean  ±  SD. Normality 
of distribution for each variable was evaluated using the Shapiro-
Wilk test and data violating the assumption of normality was 
transformed. Differences in baseline characteristics between the 
two experimental groups were assessed using independent 
samples t-tests or the non-parametric Mann-Whitney U test. 
Physical and metabolic changes in response to bed rest were 
analyzed using a mixed between-within factorial analysis of 
variance using time as the within-group factor and experimental 
group as the between-group factor (CTRL and JUMP). When 
a statistically significant interaction was found, simple main 
effects are reported as mean (M) and standard error (SE). 
Statistical analysis was performed in SPSS 26.0 (IBM Corp., 
Armonk, NY, United  States) considering a two-sided 0.05 
significance level.
In-Depth Data Analysis
An association between insulin sensitivity and fetuin-A has 
been well-established within the literature (Ochieng et al., 2018; 
Bourebaba and Marycz, 2019). In the current study, pre- to 
post-differences in insulin sensitivity and fetuin-A exhibited 
significant effects of time only, so to further explore the 
relationship between both variables additional subanalysis was 
conducted. The participant data from the two experimental 
groups were pooled and then divided into two subgroups based 
on participants who improved (↑ Matsuda, n = 6, CTRL n = 4, 
and JUMP n  =  2) or reduced (↓ Matsuda, n  =  17, CTRL 
n  =  7, and JUMP n  =  10) insulin sensitivity post-HDT bed 
rest. Paired sample t-tests were used to assess the significance 
of pre- to post-bed rest changes in physical and metabolic 
parameters in both subgroups.
RESULTS
Physical Characteristics: Body Weight, 
Body Composition, and V 
. 
O2peak
Anthropometric measurements were obtained on BDC-3 and 
HDT60 (Table  1). No significant between-group differences 
in physical characteristics were identified at baseline. Following 
60  days of HDT bed rest, body weight decreased significantly 
in both groups, with a larger reduction observed in the CTRL 
group (M  =  −3.63  kg, SE  =  0.54  kg, p  <  0.001) compared to 
the JUMP group (M  =  −2.23  kg, SE  =  0.28  kg, p  <  0.001). 
Similarly, bed rest significantly reduced lean mass, with a higher 
decline noticeable in the CTRL group (M  =  −3.91  kg, 
SE  =  0.70  kg, p  <  0.001) in comparison to the JUMP group 
(M  =  −1.34  kg, SE  =  0.32  kg, p  =  0.002). Fat mass decreased 
significantly in the JUMP group (M  =  −0.87  kg, SE  =  0.23  kg, 
p = 0.003) but did not change significantly in the CTRL group 
(M  =  0.10  kg, SE  =  0.31  kg, p  =  0.757) following HDT bed 
rest. Bone mineral content did not change significantly. Absolute 
V 
. 
O2peak, measured on BDC-8 and R + 1, decreased significantly 
in both groups after HDT bed rest, with a greater loss identified 
in the CTRL group (M  =  −1.28  L/min, SE  =  0.17  L/min, 
p  <  0.001) in comparison to the JUMP group (M  =  −0.33  L/
min, SE  =  0.15  L/min, p  =  0.049). V 
.
 O2peak, when normalized 
for changes in lean mass, decreased significantly in the CTRL 
group (M  =  −18.82  ml/kgLW/min, SE  =  2.26  ml/kgLM/min, 
p < 0.001) but did not change in the JUMP group (M = −4.58, 
SE  =  2.17, p  =  0.063) after HDT bed rest.
Metabolic Characteristics: Glucose 
Tolerance, Insulin Sensitivity, Lipid 
Metabolism, and Fetuin-A
The changes in metabolic parameters are presented in Figure 1 
and Table  2. No significant between-group differences in 
metabolic characteristics were found at baseline. Metabolic 
characteristics were corrected for changes in hemoconcentration 
TABLE 1 | Effects of 60 days HDT bed rest on measures of anthropometry and cardiorespiratory capacity.
Measurement CTRL (n = 11) JUMP (n = 12) Statistics
Pre Post Pre Post Time Int T*Int
Age (years) 28 ± 6 30 ± 7
Height (cm) 181 ± 5 181 ± 7
BMI (kg/m2) 23.33 ± 2.03 22.22 ± 1.67* 23.75 ± 1.80 23.07 ± 1.81* <0.001 0.410 0.021
BW (kg) 76.10 ± 8.06 72.47 ± 6.76* 77.85 ± 6.55 75.63 ± 6.39* <0.001 0.405 0.027
LM (kg) 56.94 ± 6.57 53.03 ± 5.11* 56.41 ± 5.18 55.08 ± 4.29* <0.001 0.731 0.002
FM (kg) 16.91 ± 3.95 17.00 ± 3.41 19.21 ± 6.42 18.34 ± 6.18* 0.055 0.412 0.018
BMC (kg) 3.14 ± 0.36 3.14 ± 0.37 3.00 ± 0.32 3.00 ± 0.32 0.605 0.355 0.800
Measurement
  CTRL (n = 10)   JUMP (n = 10)   Statistics
Pre Post Pre Post Time Int T*Int
V . O2peak (L/min) 3.85 ± 0.68 2.57 ± 0.48* 3.32 ± 0.76 2.99 ± 0.53* <0.001 0.848 0.001
V . O2peak (ml/kgLM/min) 67.55 ± 8.42 48.74 ± 9.35* 58.72 ± 10.95 54.14 ± 8.03 <0.001 0.660 <0.001
Data are presented as mean ± standard deviation (SD). Significant p < 0.05 are indicated in bold. Anthropometric measurements were taken on BDC-3 and HDT60.  
V . O2peak was measured on BDC-8 and R + 1. When a significant interaction effect was found, an asterisk (*) denotes a significant difference from pre in each intervention group.  
CTRL, control group; JUMP, jumping countermeasure group; Time, main effect of time; Int, main effect of intervention; T*Int, time*intervention interaction effect; BMI, body mass 
index; BW, body weight; LM, lean mass; FM, fat mass; BMC, bone mineral content; V. O2peak, peak aerobic capacity.
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following HDT bed rest (mean ∆PV% CTRL 0.88%, JUMP 
-2.13%). NEFA, total cholesterol, fasting glucose (glucose0), 
and 2-h insulin (insulin120) did not change significantly following 
HDT bed rest. There was a significant effect of time, but not 
intervention, for the increase in 2-h glucose (glucose120; 
p = 0.010), TG (p = 0.013), and LDL (p = 0.004) and decrease 
in HDL (p < 0.001) after HDT bed rest (Table 2). A significant 
effect of time and intervention was identified for fasting insulin 
(insulin0), which increased significantly following HDT bed 
rest and was significantly higher overall in the JUMP group 
(Table  2). There was a significant effect of time, but not 
intervention, for the increase in AUCG and AUCI post-HDT 
bed rest (Figures  1A–D). A significant main effect of time 
only was also identified for the decrease in Matsuda and 
muscle IS following HDT bed rest (Figures  1E–F). The main 
effect of time and intervention were statistically significant 
for the change in liver IS and adipose IR following HDT 
bed rest (Figures 1G–H). Liver IS decreased significantly after 
HDT bed rest and was significantly higher overall in the 
CTRL group. In contrast, adipose IR increased significantly 
following HDT bed rest and was found to be  significantly 
higher overall in the JUMP group. A significant main effect 
of time, but not intervention, was found for the increase in 







FIGURE 1 | The effects of 60 days of HDT bed rest on metabolic variables measured on BDC-5 (pre) and HDT59 (post). Data are presented as mean ± standard 
error of mean (SEM). The glucose and insulin response curve to the OGTT are displayed in (A) and (B), respectively. The 120 min area under the curve totals for 
glucose are shown in (C) and for insulin in (D). The pre to post changes in OGTT derived indexes of Matsuda, liver IS, muscle IS, and adipose IR are presented in 
(E–H). Abbreviations: CTRL, control group; JUMP, jumping countermeasure group; AUCG, area under the curve for glucose for 120 min; AUCI, area under the curve 
for insulin for 120 min; IS, insulin sensitivity; IR, insulin resistance; Time, main effect of time; Int, main effect of intervention; T*Int, time*intervention interaction effect. 
*p ≤ 0.05 and **p ≤ 0.010.
TABLE 2 | The effects of 60 days HDT bed rest on metabolic characteristics.
Measurement CTRL (n = 11) JUMP (n = 12) Statistics
Pre Post Pre Post Time Int T*Int
Glucose0 (mmol/L) 5.18 ± 0.40 5.24 ± 0.51 5.32 ± 0.64 5.47 ± 0.59 0.447 0.311 0.732
Glucose120 (mmol/L) 6.95 ± 1.01 8.51 ± 1.80 7.36 ± 1.82 7.98 ± 1.98 0.010 0.919 0.234
Insulin0 (pmol/L) 45.00 ± 13.09 51.48 ± 16.49 55.55 ± 14.92 67.22 ± 19.14 0.012 0.036 0.437
Insulin120† (pmol/L) 347.16 ± 184.12 496.38 ± 321.36 468.39 ± 281.21 492.68 ± 260.41 0.054 0.587 0.264
NEFA (mmol/L) 0.40 ± 0.13 0.41 ± 0.16 0.41 ± 0.14 0.52 ± 0.17 0.124 0.232 0.215
TG (mmol/L) 0.87 ± 0.26 1.00 ± 0.26 1.16 ± 0.45 1.21 ± 0.41 0.013 0.102 0.245
CHOL (mmol/L) 4.09 ± 0.72 4.27 ± 0.86 4.11 ± 0.57 4.06 ± 0.57 0.619 0.710 0.381
HDL (mmol/L) 1.16 ± 0.17 0.99 ± 0.19 1.08 ± 0.27 0.91 ± 0.17 <0.001 0.304 0.955
LDL (mmol/L) 2.76 ± 0.71 3.10 ± 0.71 2.73 ± 0.51 2.99 ± 0.56 0.004 0.780 0.647
Data are presented as mean ± standard deviation (SD). Significant p < 0.05 are indicated in bold. †Denotes that data were transformed for statistical analysis.  
Metabolic characteristics were measured on BDC-5 and HDT59. CTRL, control group; JUMP, jumping countermeasure group; Time, main effect of time; Int, main effect of 
intervention; T*Int, time*intervention interaction effect; Glucose0, fasting glucose; Glucose120, glucose concentrations 120 min after the glucose load; Insulin0, fasting insulin; Insulin120, 
insulin concentrations 120 min after the glucose load; NEFA, non-esterified fatty acids; TG, triglycerides; CHOL, total cholesterol; HDL, high-density lipoprotein cholesterol; LDL, 
low-density lipoprotein cholesterol.
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0.38  ±  0.16 to 0.47  ±  0.13  g/L in the CTRL group and from 
0.40  ±  0.12 to 0.54  ±  0.23  g/L in the JUMP group after 
HDT bed rest.
Subanalysis Exploring the Relationship 
Between Insulin Sensitivity and Fetuin-A
Changes in the physical and metabolic parameters in 
subgroups with decreased and increased insulin sensitivity 
following HDT bed rest are presented in Figures  2B–F and 
Supplementary Tables 1 and 2.
In the subgroup with improved insulin sensitivity following 
HDT bed rest, the pre- to post-increase in liver IS was statistically 
significant. Despite this, muscle IS and adipose IR did not 
change significantly after HDT bed rest. In subjects who became 
more insulin-sensitive following HDT bed rest, the change in 
fetuin-A was not statistically significant.
In the opposing subgroup, with reduced insulin sensitivity 
after HDT bed rest, the pre- to post-decrease in liver IS was 
statistically significant. Adipose IR increased significantly 
following HDT bed rest. The change in muscle IS was not 
statistically significant. Interestingly, in those who became less 
insulin-sensitive during HDT bed rest, circulating concentrations 
of fetuin-A significantly increased.
DISCUSSION
The main findings of the current study demonstrate that 60 days 
of HDT bed rest elicited a significant increase in fetuin-A 
concomitant with reduced insulin sensitivity, which could not 
be  mitigated by RJT. As considerable individual differences 
have been found in the responsiveness to lifestyle interventions, 
we compared changes in metabolic variables in subgroups with 
decreased and increased insulin sensitivity following HDT bed 
rest. Our results suggest that fetuin-A may have a role in the 
regulation of peripheral insulin sensitivity during bed rest and 
physical inactivity. In addition, fetuin-A has potential as a 
biomarker to track individual changes in metabolic homeostasis.
Exercise and diet countermeasures have been widely 
implemented to abrogate deconditioning during bed rest. The 
RJT protocol combined plyometric movements with high rates 
of force development with the aim of preserving musculoskeletal 
mass and strength (Kramer et  al., 2017a). The results, from 
previous publications, show that this time-efficient 
countermeasure attenuated the loss of whole body lean mass, 
leg lean mass, V 
.
 O2peak (Kramer et  al., 2017a,b), and myofiber 
size and phenotype (Blottner et  al., 2019). While RJT had 
protective effects for muscle function, it could not prevent the 
dysregulation of glucose and lipid metabolism. Similar results 
were reported following flywheel exercise (Bergouignan et  al., 
2006) and the authors, in this case, suggested that insufficient 
energy expenditure during the training sessions may be  the 
key factor. While the RJT is a form of high intensity interval 
training consisting of 48 jumps and 30 hops, the overall workload 
may not be  sufficient to improve insulin sensitivity. There was 
a decrease in fat mass (0.9  kg), indicating a negative energy 
balance in the JUMP group but this may be due to the challenges 




FIGURE 2 | (A) Circulating fetuin-A in the CTRL and JUMP groups before and after 60 days of HDT bed rest. (B–F) The effect of HDT bed rest on fetuin-A and 
OGTT derived indexes of insulin sensitivity and insulin resistance when subjects were divided into two subgroups based on an increase (n = 6) or decrease (n = 17) 
in insulin sensitivity (Matsuda) post-HDT bed rest. Data are presented as mean ± SEM. Abbreviations: CTRL, control group; JUMP, jumping countermeasure group; 
IS, insulin sensitivity; IR, insulin resistance; Time, main effect of time; Int, main effect of intervention; T*Int, time*intervention interaction effect. *p ≤ 0.05, **p ≤ 0.010, 
and ***p ≤ 0.001.
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Another challenge for countermeasure design and 
implementation is the individual variation in response to lifestyle 
interventions (Bouchard and Rankinen, 2001; Solomon, 2018; 
O’Donoghue et  al., 2019). While a specific exercise program 
may, on average, be  effective there can be  a broad range in 
the individual response. This is particularly important for long-
term missions in microgravity, where a standard countermeasure 
program may not confer the same benefit to all the astronauts. 
It will be  important to have individualized countermeasure 
programs that can be  monitored and adjusted depending on 
the response. While changes in muscle mass can be  observed 
with relative ease, monitoring changes in metabolism is more 
challenging in microgravity. The role of circulating biomarkers 
may serve as a simple and effective strategy to track metabolic 
changes on the health continuum and guide countermeasure 
recommendations. Previous research has reported that the 
beneficial and detrimental effects of physical activity and inactivity, 
respectively, are linked with changes in circulating biomarkers, 
which are key messengers for inter-organ communication (Pedersen 
and Febbraio, 2012; Ennequin et  al., 2019; Mika et  al., 2019).
Fetuin-A is a multifunctional glycoprotein that is predominately 
synthesized and secreted by hepatocytes (Bourebaba and Marycz, 
2019) and associated with insulin action (Ochieng et  al., 2018). 
To the best of our knowledge, fetuin-A has not been previously 
reported following bed rest and we  report a significant increase 
in circulating fetuin-A following 60  days of HDT bed rest, 
irrespective of the experimental group. The regulation of hepatic 
fetuin-A secretion is incompletely understood (Haukeland et al., 
2012). Previous research has reported that fetuin-A mRNA 
expression in the liver correlated positively with hepatic triglyceride 
content and homeostatic model of insulin resistance (HOMA-
IR) and these associations remained significant after adjustment 
for BMI (Peter et  al., 2018). These findings were supported by 
a cross-sectional study reporting higher fetuin-A in subjects 
with elevated liver fat content (Stefan et  al., 2006). Analysis of 
longitudinal data following a lifestyle intervention found that 
the changes in fetuin-A paralleled the changes in liver fat (Stefan 
et  al., 2006). Collectively, this evidence presents fetuin-A as a 
possible biological and predictive marker of metabolic disease.
Fetuin-A is also responsive to exercise training and a number 
of studies have reported a decrease in circulating levels with 
accompanying improvements in body composition, liver fat, 
and insulin sensitivity (Malin et  al., 2013, 2014). Reductions 
in fetuin-A following aerobic exercise training have been 
attributable to decreases in waist circumference and body weight 
and increases in adiponectin, an insulin sensitizing hormone 
(Zhang et al., 2018). Additionally, favorable changes in fetuin-A, 
liver fat and insulin sensitivity have also been reported following 
long-term (12  weeks) aerobic and resistance exercise training 
(Lee et  al., 2017). A recent meta-analysis reported that both 
aerobic and resistance training significantly reduced fetuin-A 
in dysglycemic and overweight/obese individuals when performed 
at a moderate or vigorous intensity, with a volume of 60  min 
per session and a minimum frequency of 4–7 sessions per 
week (Ramírez-Vélez et  al., 2019).
In this study, we  found that circulating concentrations of 
fetuin-A and insulin sensitivity were not significantly affected 
by RJT performed during HDT bed rest. This may be  due to 
the type, intensity, and duration of the exercise protocol, which 
was primarily designed to preserve muscle mass and function. 
In addition, the physical inactivity of bed rest is the primary 
intervention and the exercise countermeasure in this case is 
designed to maintain rather than enhance physiological function. 
We  observed a significant reduction in whole body insulin 
sensitivity, concomitant with an increase in circulating TG after 
60  days HDT bed rest in energy-balanced conditions. These 
findings are in agreement with other bed rest studies (Bergouignan 
et  al., 2009; Rudwill et  al., 2015; Kenny et  al., 2017), which 
support links between the decrease in muscle contraction and 
elevated TG (Bergouignan et al., 2011), decreases in the amount 
and activity of key proteins associated with muscle glucose 
uptake (Biensø et al., 2012), and altered mitochondrial function 
(Kenny et  al., 2017). The observation that whole body and 
liver insulin sensitivity improved in a subgroup of bed rest 
participants is intriguing and supports the current emphasis 
on personalized medicine approaches to disease treatment. 
Interestingly, the improvement in insulin sensitivity was greater 
in the CTRL group than in the JUMP group. It has previously 
been highlighted that there is substantial inter-individual 
variability in physiological responses following lifestyle 
interventions (Bouchard and Rankinen, 2001; Solomon, 2018; 
O’Donoghue et  al., 2019). In addition, the genes and pathways 
underlying the response to exercise training and physical 
inactivity differ (Booth et al., 2012; Pillon et al., 2020). Therefore, 
it is important to learn more about the possible mediators of 
the variation in insulin sensitivity following bed rest.
Our analysis identified six participants (26%) that improved 
insulin sensitivity following HDT bed rest. In addition, there 
were no significant changes in fetuin-A, fasting glucose, or 
TG in this subgroup. One possibility is that the improvement 
in whole body insulin sensitivity may be  an indirect effect of 
liver metabolism. The amount of intra-hepatic lipid (IHL) is 
strongly linked to liver and whole body insulin resistance (Mu 
et  al., 2018; Trouwborst et  al., 2018). If liver insulin sensitivity 
does not decrease, it is possible that the release of fetuin-A 
would be  attenuated and the negative effect on peripheral 
tissues would be  mitigated (Figure  3). In support of this 
hypothesis, fetuin-A levels were found to be significantly higher 
in metabolically-unhealthy compared with metabolically-healthy 
obese subjects (Khadir et  al., 2018). Fetuin-A knockout (KO) 
mice display enhanced insulin sensitivity, improved glucose 
tolerance, and lowered plasma lipid content (Mathews et  al., 
2002). When fed a high fat diet, fetuin-A KO mice remain 
insulin-sensitive, are resistant to weight gain and have less 
adiposity than wild-type controls. As there is inter-individual 
variation in IHL following lifestyle interventions (Winn et  al., 
2018), it is possible that fetuin-A could be a driver of peripheral 
insulin resistance and a biomarker to track the physiological 
responsiveness to bed rest and physical inactivity.
Despite the highly controlled nature of this bed rest study, 
there are some limitations to acknowledge. Firstly, the sample 
size for parallel-designed bed rest studies is generally low, in 
the order of 8–12 participants per group (Bergouignan et  al., 
2006, 2009; Rudwill et  al., 2015, 2018; Kenny et  al., 2017). 
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It is possible that the small sample size in the subgroup with 
improved insulin sensitivity is too small for a definite conclusion, 
and therefore, we  suggest that further studies are required to 
investigate the potential role of fetuin-A in the regulation of 
whole body insulin sensitivity following HDT bed rest. Secondly, 
although it was not the objective of this study, we  did not 
obtain any measurements of liver fat precluding our ability to 
fully explore the association between fetuin-A and hepatic 
insulin resistance in response to physical inactivity; this requires 
further investigation. Thirdly, an OGTT was used to estimate 
insulin sensitivity. While a euglycaemic-clamp is the gold 
standard measure, it was not possible in the current study. 
However, the OGTT sufficiently reflects changes in glucose 
tolerance and the measurement of whole body insulin sensitivity 
using the OGTT has been validated previously in healthy 
non-overweight adults (Trikudanathan et  al., 2013). Finally, 
the results of this study have been obtained from healthy, lean 
adult males and similar investigations will need to be extended 
to other populations (e.g., women, elderly, and metabolically 
unhealthy) to determine the specific links with disease etiology.
In conclusion, we  report that 60  days of HDT bed rest led 
to a significant increase in circulating fetuin-A and decreased 
insulin sensitivity, which could not be  ameliorated by RJT. 
Exploring individual responses to lifestyle interventions is a 
growing area of interest in personalized medicine. While HDT 
bed rest reduced insulin sensitivity at the group level, there 
was considerable individual responses, including a subgroup 
for which insulin sensitivity improved. We  propose that the 
regulation of insulin sensitivity is related to circulating fetuin-A, 
which is attenuated when liver metabolism is maintained. 
Collectively, our results show that fetuin-A is a candidate 
biomarker to assess the physiological responses to bed rest 
and physical inactivity.
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